Drugs / Astagraf XL
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ASTAGRAF XL | — | 2018-11-29 | fda.gov ↗ |
| Approved | US (FDA) | ASTAGRAF XL | — | 2013-07-19 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02221583 | May 2014 → Feb 2015 | end stage renal failure | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astagraf XL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221583 ↗ |